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Question:  
Our hospital blood bank has started using platelet additive solution (PAS) platelets and psoralen 
treated platelets.  What are the advantages and disadvantages of these different types of platelets? 
 
 
Answer:  
Platelet additive solution (PAS) platelets 
have had the majority (60-70%) of the 
plasma removed and replaced with a 
crystalloid solution.  Since antigens in the 
plasma are responsible for allergic 
transfusion reactions, PAS platelets have a 
significantly reduced incidence of this type 
of reaction and are a good choice for 
patients who experience recurrent or severe 
allergic reactions to platelet transfusions.  
The corrected count increment (CCI), a 
measurement of patient response to platelet 
transfusion, is slightly lower with PAS 
platelets than standard apheresis platelets at 
one hour post transfusion, however there is 
no significant difference in CCI at 24 hours.  
The cost of PAS platelets is similar to 
standard apheresis platelet units. 
     
Psoralen treated platelet and plasma 
products have been in use in Europe for over 
a decade, and one such treatment (brand 
name Intercept) was approved by the Food 
and Drug Administration (FDA) for use in 
the United States in 2014.  Psoralen treated 
platelets start with a standard apheresis 
platelet collection, which is then treated with 
a psoralen drug (amotosalen) followed by 
UV light.  During this process, the psoralen 
intercalates into nucleic acids and becomes 
fixed, preventing DNA or RNA replication.  
Platelets remain unaffected, but viruses, 
bacteria, and donor white blood cells present 
in the bag are inactivated.  The majority of 
the psoralen is then removed from the bag, 
and the platelet unit may then be transfused 
to a patient.   
 
Potential advantages of psoralen 
treated platelets include a reduced risk of 
transfusion transmitted infections, including 
bacterial contamination of the unit.  Psoralen 
treated platelets do not require an initial 
culture to screen for bacterial contamination 
before they are released from the donor 
center, which may effectively increase the 
shelf life of the unit and reduce wastage due 
to expiration.  Since the drug prevents 
replication of donor white blood cells in the 
unit, there is no need for irradiation of 
psoralen treated platelets for prevention of 
transfusion associated graft versus host 
disease.  Psoralen treated platelets will also 
meet a new FDA requirement, expected to 
be finalized later this year, requiring blood 
banks to take additional steps to prevent 
transfusion of platelets contaminated with 
bacteria. 
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Psoralen treated platelets cost about 
$100 more per unit than standard apheresis 
platelet units, but this increased cost should 
be weighed against the cost savings from 
eliminating extra charges for 
Cytomegalovirus (CMV) negative and/or 
irradiated platelets, not having to perform 
daily bacterial testing of platelet units to 
meet the new FDA requirement, and the 
potential for decreased platelet expiration 
rates due to an increased effective shelf life.   
 
Patients with allergies to psoralens 
should not receive psoralen treated platelets.  
An early US study of psoralen treated 
platelets found a small increased risk of 
acute respiratory distress syndrome (ARDS) 
compared to standard platelets, however an 
independent blinded repeat analysis using 
standard diagnostic criteria for both groups 
found no significant difference in ARDS 
between the two types of platelets; the initial 
difference was attributed to inconsistent 
reporting between study sites.  A larger 
study to evaluate this potential adverse 
reaction is currently in progress. 
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